Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.
Conditions
Brief summary
For BPaLM interventional arm: proportion of study participants achieving sustained treatment success at 18 months after study treatment start, according to 2021 WHO definitions, in the absence of permanent addition of any TB drug to the regimen or >4 consecutive weeks treatment interruption or >4 weeks treatment prolongation. For the historical cohort: proportion of patients achieving treatment success (2021 WHO definitions).
Interventions
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For BPaLM interventional arm: proportion of study participants achieving sustained treatment success at 18 months after study treatment start, according to 2021 WHO definitions, in the absence of permanent addition of any TB drug to the regimen or >4 consecutive weeks treatment interruption or >4 weeks treatment prolongation. For the historical cohort: proportion of patients achieving treatment success (2021 WHO definitions). | — |
Countries
France
Outcome results
None listed